NCT06512311

Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening

Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial (ATTRACT)

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 240 (estimated)
• Sponsor: Medical University of Vienna · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Patient derived cell line (PDC) -based drug screening will be applied to formulate a personalized treatment approach.

Detailed description

Patient derived cell line (PDC) -based drug screening will be applied to formulate a personalized treatment approach. Patients will be randomized between the investigational group receiving in addition to standard histology analysis also the PDC-based drug screening and the standard group receiving only standard histology analysis. Outcome results will be compared in a randomized, interventional clinical performance study. The PDC-based drug screening will be performed only in accordance with the approved Performance Study Plan on subjects who have signed an informed consent form.

Conditions

• Glioblastoma

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	CBMed Drug Screening Plattform	The main devices used within the drug screening process are purchased from PerkinElmer, Liconic Instruments, BioTek and Beckman Coulter Diagnostics.

Timeline

• Start date: 2024-07-10
• Primary completion: 2030-12-31
• Completion: 2031-12-31
• First posted: 2024-07-22
• Last updated: 2026-04-14

Locations

1 site across 1 country: Austria